Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Stock Information for Propanc Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Propanc Biopharma Inc.

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.